Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Polio-Pipeline Review, H1 2015

Polio-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Polio-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Polio-Pipeline Review, H1 2015', provides an overview of the Polio's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polio, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polio and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Polio

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Polio and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Polio pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Polio

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Polio Overview 8

Therapeutics Development 9

Pipeline Products for Polio-Overview 9

Pipeline Products for Polio-Comparative Analysis 10

Polio-Therapeutics under Development by Companies 11

Polio-Therapeutics under Investigation by Universities/Institutes 12

Polio-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Polio-Products under Development by Companies 17

Polio-Products under Investigation by Universities/Institutes 18

Polio-Companies Involved in Therapeutics Development 19

Beijing Minhai Biotechnology Co., Ltd 19

Beijing Tiantan Biological Products Co., Ltd. 20

Bharat Biotech International Limited 21

Biological E. Limited 22

Codagenix, Inc. 23

Grifols, S.A. 24

Panacea Biotec Limited 25

Sanofi Pasteur SA 26

Sentinext Therapeutics Sdn Bhd 27

Sinovac Biotech Ltd. 28

Polio-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Combination Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

immune globulin (human)-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

IPVGVI-3000-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

polio (bivalent) virus like particle vaccine-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

polio (monovalent) vaccine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

polio [sabin] vaccine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

polio vaccine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

polio vaccine-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

polio vaccine-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

polio vaccine [types 1, 2, 3] (monovalent)-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

poliomyelitis vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

PR-5I-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

V-073-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Polio-Recent Pipeline Updates 58

Polio-Dormant Projects 59

Polio-Discontinued Products 60

Polio-Product Development Milestones 61

Featured News & Press Releases 61

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

Number of Products under Development for Polio, H1 2015 9

Number of Products under Development for Polio-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Comparative Analysis by Unknown Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Polio-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 19

Polio-Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 20

Polio-Pipeline by Bharat Biotech International Limited, H1 2015 21

Polio-Pipeline by Biological E. Limited, H1 2015 22

Polio-Pipeline by Codagenix, Inc., H1 2015 23

Polio-Pipeline by Grifols, S.A., H1 2015 24

Polio-Pipeline by Panacea Biotec Limited, H1 2015 25

Polio-Pipeline by Sanofi Pasteur SA, H1 2015 26

Polio-Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2015 27

Polio-Pipeline by Sinovac Biotech Ltd., H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Assessment by Combination Products, H1 2015 30

Number of Products by Stage and Target, H1 2015 32

Number of Products by Stage and Mechanism of Action, H1 2015 34

Number of Products by Stage and Route of Administration, H1 2015 36

Number of Products by Stage and Molecule Type, H1 2015 38

Polio Therapeutics-Recent Pipeline Updates, H1 2015 58

Polio-Dormant Projects, H1 2015 59

Polio-Discontinued Products, H1 2015 60

List of Figures

Number of Products under Development for Polio, H1 2015 9

Number of Products under Development for Polio-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 29

Assessment by Combination Products, H1 2015 30

Number of Products by Top 10 Targets, H1 2015 31

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 35

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36

Number of Products by Top 10 Molecule Types, H1 2015 37

Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

Bharat Biotech International Limited

Biological E. Limited

Codagenix, Inc.

Grifols, S.A.

Panacea Biotec Limited

Sanofi Pasteur SA

Sentinext Therapeutics Sdn Bhd

Sinovac Biotech Ltd.

Polio Therapeutic Products under Development, Key Players in Polio Therapeutics, Polio Pipeline Overview, Polio Pipeline, Polio Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com